Short answer
Twist Bioscience Corp (TWST) filed its fiscal 2026 10-K annual report with the SEC on Nov 16, 2026. It reported revenue of $459M (+22.0% year over year) and net income of −$130M.
- Top risk flagged: Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints
FY2026 key financial metrics · XBRL
- Revenue
- $459M
- +22.0% YoY
- Net income
- −$130M
- −67.6% YoY
- Operating margin
- -30.4%
- +5.8 pp YoY
- EPS (diluted)
- −$2.08
- −60.0% YoY
- ROE
- -14.7%
- +1.8 pp YoY
- Operating cash flow
- −$41M
- +13.0% YoY
Source: XBRL data from the Twist Bioscience Corp (TWST) FY2026 10-K on SEC EDGAR. USD.
Twist Bioscience Corp FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Silicon-based DNA synthesis platform: customizable DNA, proteins and sequencing workflow solutions across life sciences markets
- Fiscal 2026 segment reorganization: combined synthetic biology and antibody discovery into DNA Synthesis and Protein Solutions
- AI drug discovery emphasis: Twist became a protein and data partner, with substantially increased customer demand
- February 2026 bispecific expansion: co-exclusive Invenra B-Body license and minority equity investment
- Revenue $459.4 million from approximately 4,100 customers, with 1,080 employees as of September 30, 2026
Management Discussion & Analysis
- Revenue $459.4M, up 22% YoY from $376.6M, driven by DNA Synthesis and Protein Solutions and NGS Applications
- Gross margin 52.4% vs 50.7%; operating loss $139.5M vs $136.3M
- Best segment DNA Synthesis and Protein Solutions, revenue $221.9M, up $53.4M; weakest growth NGS Applications, revenue $237.5M, up $29.4M
- Operating cash use $41.4M; capex $47.6M; financing cash $446.7M, including $327.7M offering proceeds and $97.1M ATM proceeds
- Outlook: AI-enabled drug discovery demand expected to grow in fiscal 2027; approximately $150M capex planned over two years, with reimbursement and regulatory risks
Risk Factors
- Biosecurity regulation: Executive Order 14292 and proposed H.R. 3029 could increase nucleic-acid screening costs, turnaround times, and fulfillment constraints
- Geopolitical exposure: International customers generated 41% of fiscal 2026 revenue amid tariffs, Russia-China tensions, and Israel-Hamas conflict
- Supply-chain vulnerability: One single-source supplier provides a critical DNA-synthesis component Twist cannot manufacture internally
- Competitive disruption: Integrated DNA Technologies, GenScript, and emerging silicon-chip technologies threaten Twist’s platform advantage
- Financial risk: Net loss $130.2 million and accumulated deficit $1,449.8 million as of September 30, 2026, with potential further equity dilution
Generated from the filing text; verify against the original. How to read a 10-K
Other Twist Bioscience Corp annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.